Date: 2016-01-04
Type of information: Nomination
Compound:
Company: Inovio Pharmaceuticals (USA - PA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 4, 2016, Inovio Pharmaceuticals announced it has appointed Prakash Bhuyan, M.D, Ph.D., as Vice President, Clinical Development. Dr. Bhuyan will lead the clinical development of Inovio’s programs to treat HPV-related pre-cancers (dysplasia). Inovio will take VGX-3100, its treatment for cervical dysplasia caused by the human papillomavirus (HPV), into a phase 3 registration study this year. He will report to Dr. Mark Bagarazzi, Chief Medical Officer. Prior to joining Inovio, Dr. Bhuyan was Senior Director, Pfizer Vaccine Research, where he led the pivotal clinical study that helped achieve FDA approval in 2014 of the first meningococcal B vaccine to be licensed in the U.S. Prior to Pfizer, Dr. Bhuyan directed the development and execution of multiple vaccine clinical trials for 4 licensed vaccines at Merck&Co and successfully led an investigational hexavalent pediatric vaccine from phase 2 into phase 3 trials. He earned his M.D. and his Ph.D. in Immunology from the University of Texas Southwestern Medical Center. He completed his fellowship in Infectious Diseases at the University of Pennsylvania, where he currently serves as adjunct assistant professor.
Financial terms:
Latest news:
